InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to report its Q1 2024 financial results. In conjunction with that, the company will also host a corporate conference call. According to the announcement, the company has scheduled to call on Aug. 10, 2023, at 4:30 p.m. ET. During the call, company leaders will provide a corporate update and release financial results for its fiscal year 2024 first quarter, the period ended June 30, 2023. Those interested in participating on the call can dial toll-free 1-800-954-1051 in the United States or 1-212-231-2924 internationally, then use conference ID 22027732. The company noted that a replay of the call will be available. Those interested in accessing the replay can dial toll-free 1-844-512-2921 within the United States or 1-412-317-6671 internationally, then use replay access ID number 22027732.
To view the webcast, visit https://ibn.fm/MnFvJ
To view the full press release, visit https://ibn.fm/EloQ1
About Vistagen Therapeutics Inc.
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than treatments that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), PH15, PH80 and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherine dose nasal sprays and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information about the company, please visit www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork